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Abstract 
      Human Immunodeficiency virus (HIV) infection is associated with increased of developing heart disease. 
Information on cardiac status in HIV infected in Nigerians is lacking. We assessed the impact of HIV infection 
on serum Myoglobin, Troponin, total CK, CK-MB, LDH and AST of HIV infected adults presenting at Nnamdi 
Azikiwe University Teaching Hospital Nnewi, Anambra State. 
The aim of this study is to determine some cardiac biomarkers in adult HIV seropositive participants, blood 
samples collected from the 300 randomly recruited participants were used for HIV screening, CD4
+
 T cell count, 
serum Myoglobin, Troponin, total CK, CK-MB, LDH and AST. Standard Laboratory methods were used for the 
analysis. The results showed that the mean serum Myoglobin and Troponin levels were significantly higher in 
symptomatic HIV participants not on antiretroviral therapy (ART) compared with asymptomatic HIV 
participants at P< 0.05, in each case. Also, the mean serum Myoglobin and Troponin levels were significantly 
higher in symptomatic HIV participants not on ART compared with HIV asymptomatic HIV participants at 
P<0.05 in each case. Again, the mean serum total Creatine kinase, CK-MB, LDH and AST were significantly 
higher in symptomatic HIV participants not on ART compared with asymptomatic HIV participants at P<0.05 
respectively. Similarly, the mean serum total Creatine kinase, CK-MB, LDH and AST were significantly higher 
in symptomatic HIV participants not on ART compared with HIV seronegative control subjects at P<0.05 in 
each case. Once again, the mean serum total Creatine kinase, CK-MB and AST were significantly higher in 
asymptomatic HIV participants compared with HIV seronegative control subjects at P<0.05 respectively. 
Increased levels of some cardiac markers were seen in HIV infected participants. 
 
Keywords: HIV, cardiac markers, participants. 
 
  1 Introduction 
 
     Human immunodeficiency virus (HIV) is a lentivirus that breaks down the body’s immune system, infects 
CD4 lymphocytes, depletes them and gradually leads to Acquired immunodeficiency syndrome (AIDS) which is 
a fatal illness (Rasool et al, 2008). Infection with HIV leads to a progressive impairment of cellular functions, 
which is characterized by a gradual decline in blood CD4
+ 
T cell counts thereby predisposes the individual to a 
wide variety of opportunistic bacterial, fungal, viral, protozoal infections and cancerous growth (Khiangte et al, 
2007). 
     Reports have it that individuals infected with HIV have increased risk of developing cardiovascular diseases 
(Sudano et al, 2006) such as pericarditis (Sudano et al, 2006), endocarditis (Miro et al, 2003). There are some 
cardiac biomarkers used for measuring heart function especially in heart diseases (Vasadevan et al, 2011). 
   In this study, cardiac protein markers such as Myoglobin, Troponin and cardiac enzyme markers such as total 
CK, CK-MB, LDH and AST were used to evaluate the cardiac function of adult HIV seropositives in Nnewi. 
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2  Materials and Methods 
2.1 Subjects 
      The study was conducted in Nnamdi Azikiwe University (NAUTH), Nnewi in Anambra state, South East 
Nigeria. Three hundred subjects were randomly recruited for this study. Using the World Health Organization 
(6), staging for HIV as a guide, the participants were grouped, comprising of 100 symptomatic HIV subjects on 
ART, 100 symptomatic HIV subjects not on ART and 100 (male = 49; female = 51) HIV seronegative control 
subjects. These participants have no history of any disease which was obtained using questionnaire and they 
were randomly recruited from the voluntary and counseling unit (VCT) of NAUTH. Ethical approval was sorted 
and obtained from the NAUTH ethics committee and informed consent was obtained from the participants. 
 
2.2 Sample collection 
    Six milliliter (6 ml) of fasting blood samples were collected from all the participants in this study. 2ml of 
blood samples were collected into EDTA sample tubes for HIV screening and CD4+ T cell count. The remaining 
4 ml of blood sample were collected into plain tube and allowed to clot, centrifuged, the serum separated and 
analyzed for serum Myoglobin, Troponin, CK, CK-MB, LDH and AST levels.  
 
2.3 Quality control measures 
         Quality control sera were run along test in each batch of analysis these were compared with the reference 
values of the control sera. Standard deviation and coefficient of variation were calculated on them. 
 
2.4 Methods of assaying 
2.4.1 Determination of Antibodies to HIV-1 and HIV-2 in Human plasma. 
Procedure 
    Two different methods were used, namely, Abbott determine TM HIV -1 and HIV-2 kit, which is an in-vitro 
visually read immunoassay (Abbott Japan Co.Ltd.Tokyo, Japan) and HIV-1 and 2 STAT-PAK Assay kit, which 
is an Immunochromatographic test for the quantitative detection of antibodies to HIV-1 and HIV-2 in Human 
plasma (CHEMBIO Diagnostic system, Inc, New York, USA). For the Abbott determine TM HIV -1 and HIV-2 
kit, the procedure described by the manufacturer was used for the analysis. Briefly, 50 μl of participant serum 
samples separated from the corresponding whole blood samples in EDTA were applied to the appropriately 
labeled sample pad. After 15 minutes but not more than 60 minutes of sample application, the result was read. 
This method has inherent quality control that validates the results. For the Immunochromatographic method for 
HIV -1 and HIV-2, the procedure described by the manufacturer was used for the analysis. In brief, 5 ml of 
participant’s plasma was dispensed into the sample well in the appropriately labeled sample pad. Three drops of 
the buffer supplied by the manufacturer was added into the appropriately labeled sample pad. The results of the 
test were read at 10 minutes after the addition of the running buffer. This method has inherent quality control and 
validates the results.  
2.4.2 Determination of CD4
+
T cells counts by CyFlows SL-Green 
Procedure 
   200 ml EDTA whole blood was collected into PARTEC test tubes (Rohren tube). Then 20 µl of CD4
+
 T 
antibody was added into the tube. The contents was mixed and incubated in the dark for15 minutes at room 
temperature. 800 ml of CD4 buffer was added into the mixture and mixed gently. Then the Partec tube was 
plugged on the Cyflow counter and the CD4
+
 T cells were displayed as peaks and interpreted as figures. 
2.4.3 Quantitative determination of Troponin I (cTnI) in human sera 
. 
Standard cTn1 Calibration Curve.  
   Calibration curve was prepared by the method as described by the manufacturer (Life Sciences Advanced 
Technologies, Inc, USA). The following concentrations of standards of cTn1 were provided: 0 ng/ml, 2 ng/ml, 
7.5 ng/ml, 30 ng/ml and 75 ng/ml. Each standard was treated in the same procedure as described for the test 
sample. A standard calibrate curve was prepared by plotting concentrations (ng/ml) of these standards against 
their absorbances. 
Procedure 
   The procedure was as described by the manufacturer (Life Sciences Advanced Technologies, Inc, USA). 100 
µl of standards, specimens and controls were dispensed into appropriates microtiter wells. 100 µl enzyme 
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conjugate reagent was dispensed into each well, gently mixed for 30 seconds and incubated at room temperature 
for 90 minutes. The incubation mixture was emptied into a sink, rinsed 5 times with deionized water and the 
residual water droplet absorbed with absorbent paper. Then, 100 µl of tetramethylbenzidine (TMB) reagent was 
added into each well, gently mixed for 10 secs and allowed to developed colour at room temperature for 20 
minutes. The reaction was stopped by the addition of 100 µl hydrochloric acid into each well and gently mixed 
for 30 seconds. 
   The absorbance of the standard and test were read within 15 minutes of performing the analysis, after zeroing 
the machine with blank at 450nm wavelength using spectrophotometer. The concentrations of cTn1 in specimens 
were extrapolated from the graph. 
2.4.4 Quantitative determination of Myoglobin in human sera 
Standard myoglobin Calibration Curve. 
   Calibration curve was prepared by the method as described by the manufacturer (Life Sciences Advanced 
Technologies, Inc, USA). The following concentrations of standards of myoglobin were provided and they were 
prediluted 10 fold: 0 ng/ml, 25 ng/ml, 100 ng/ml, 250 ng/ml, 500 n/g and 1000 ng/ml. Each standard was treated 
in the same procedure as described for the test sample. A standard calibrate curve was prepared by plotting 
concentrations (ng/ml) of these standards against their absorbances. 
Procedure 
     The procedure was as described by the manufacturer (Life Sciences Advanced Technologies, Inc, USA). 20 
µl of already 10 fold diluted standards, 10 fold diluted specimen and 10 fold diluted controls was dispensed into 
appropriates microtiter wells. 200 µl enzyme conjugate reagent was dispensed into each well, gently mixed for 
30 seconds and incubated at room temperature for 45 minutes. The incubation mixture was emptied into a sink, 
rinsed 5 times with deionized water and the residual water droplet absorbed with absorbent paper. Then, 100 µl 
of tetramethylbenzidine (TMB) reagent was added into each well, gently mixed for 5 seconds and allowed to 
developed colour at room temperature for 20 minutes. The reaction was stopped by the addition of 100 µl 
hydrochloric acid into each well and gently mixed for 30 seconds. 
    The absorbance of the standard and test were read within 15 minutes after zeroing the machine with blank at 
450 nm wavelength using spectrophotometer. The concentrations of myoglobin in specimens were extrapolated 
from the graph. 
2.4.5 Quantitative determination of total Creatine kinase (CK) in Human sera 
Procedure 
    The procedure was as described by the manufacturer (Agappe Diagnostics, Switzerland). 100 µl of standards, 
specimens and controls were dispensed into appropriates test-tubes. 1000 µl of working reagent (D-glucose 125 
mmol/L, N-Acetyl-L-cysteine 25 mmol/L, magnesium acetate, 12.5 mmol/L, NADP 2.4 mmol/L, EDTA 2 
mmol/L, Hexokinase > 6800 U/L, creatine phosphate 250 mmol/L, ADP 15.2 mmol/L, AMP, 25 mmol/L, 
Diadenosine pentaphosphate 103 mmol/L, G-6-PDH > 8800 U/L) were dispensed into each test-tube 
respectively, gently mixed and incubated at 37 
o
C for 1 minute. The change in absorbance per minute was 
measured within 3 minutes at 340 nm. 
Calculation: 
     Creatine kinase Activity (U/L) = (▲OD/ 3 minutes) x 4127. 
2.4.6 Quantitative determination of Creatine kinase (CK)- MB in Human sera 
Procedure 
The procedure was as described by the manufacturer (Agappe Diagnostics, Switzerland). 40 µl of standards, 
specimens and controls were dispensed into appropriates test-tubes. 1000 µl of working reagent (imidazole (pH 
6.7), 125 mmol/L, D-glucose 25 mmol/L, N-Acetyl-L-cysteine 25 mmol/L, magnesium acetate, 12.5 mmol/L, 
NADP 2.52 mmol/L, EDTA 2.02 mmol/L, Hexokinase > 6800 U/L, creatine phosphate 250 mmol/L, ADP 15.2 
mmol/L, AMP, 25 mmol/L, Diadenosine pentaphosphate 103 mmol/L, G-6-PDH > 8800 U/L) were dispensed 
into each test-tube respectively, gently mixed and incubated at 37 
o
C for 100 seconds. The change in absorbance 
per minute was measured within 3 minutes at 340 nm. 
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Calculation: 
       Creatine kinase –MB Activity (U/L) = (▲OD/ 3 minute) x 8254. 
2.4.7 Quantitative determination of Aspartate amino transferase (AST). 
Procedure 
  The procedure was as described by the manufacturer (Agappe Diagnostics, Switzerland). 100 µl of standards, 
specimens and controls were dispensed into appropriates test-tubes. 1000 µl of working reagent (Tris buffer, 88 
mmol/L, L-aspartate, 260 mmol/L,  MDH, > 600 U/L, LDH > 900 U/L, NADH, 0.20 mmol/l, α- ketoglutarate  
12 mmol/L)) were dispensed into each test-tube respectively, gently mixed and incubated at 37 
o
C for 100 
seconds. The change in absorbance per minute was measured within 3 minutes at 340 nm. 
 
Calculation: 
    AST Activity (U/L) = (▲OD/ 3 minutes) x 1768 
2.4.8 Quantitative determination serum lactate dehydrogenase 
Procedure 
    The procedure was as described by the manufacturer (Agappe Diagnostics, Switzerland). 10 µl of standards, 
specimens and controls were dispensed into appropriates test-tubes. 1000 µl of working reagent (Tris buffer, 80 
mmol/L, pyruvate 1.6 mmol/L, sodium chloride, 200 mmol/L NADH, 240 mmol/L) were dispensed into each 
test-tube respectively, gently mixed and incubated at 37 
o
C for 1 minute. The change in absorbance per minute 
was measured within 3 minutes at 340 nm. 
Calculation: 
    LDH Activity (U/L) = (▲OD/ 3 minutes) x 16030. 
2.5 Data analysis 
     The result of the analysis was statistically analyzed. Students’t-test and one way analysis of variance 
(ANOVA) were used to compare means. The analyses were performed with the use of Statistical Package for 
Social Sciences (SPSS) statistical software package, version 16.0. P <0.05 is considered statistically significant. 
 3. Results 
    The mean serum Myoglobin and Troponin I (ng/mL) levels were significant different amongst the groups at P 
= 0.000 (F = 40.18 and 709.44) respectively. 
     Between group comparison showed that the mean serum Myoglobin and Troponin I levels were significantly 
higher in symptomatic HIV infected subjects not on ART compared with asymptomatic HIV individuals 
(P<0.05, in each case).  
     Also, the mean serum Myoglobin and Troponin I levels were significantly higher in symptomatic HIV 
infected subjects not on ART compared with HIV seronegative control subjects (P<0.05, in each case).  
     Similarly, the mean serum Myoglobin and Troponin I levels were significantly higher in asymptomatic HIV 
infected subjects compared with HIV seronegative control subjects (P<0.05, in each case). 
      However, the CD4+ T cell counts was significantly lower between symptomatic HIV infected subjects not on 
ART compared with asymptomatic HIV infected subjects, between symptomatic HIV infected subjects not on 
ART compared with HIV seronegative control subjects and between asymptomatic HIV infected subjects 
compared with HIV seronegative control subjects  (P<0.05, in each case) 
       The mean serum activities of total CK, CK-MB, LDH and AST (IU/L) levels were significant different 
amongst the groups at P = 0.000 (F = 96.98; 245.89, 294.54.60 and 75.65) respectively. 
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    Between group comparison showed that the mean serum activities of total CK, CK-MB, LDH and AST levels 
were significantly higher in symptomatic HIV infected subjects not on ART compared with asymptomatic HIV 
infected subjects at p<0.05 respectively.  
     Also, between group comparison showed that the mean serum activities of total CK, CK-MB, LDH and AST 
levels were significantly higher in symptomatic HIV infected subjects not on ART compared with HIV 
seronegative subjects (p<0.05, in each case). 
   Similarly, the mean serum activities of total CK, CK-MB and AST levels were significantly higher in 
asymptomatic HIV infected subjects compared with HIV seronegative subjects (p<0.05, respectively). But the 
mean serum activity of LDL was the same in asymptomatic HIV infected subjects compared with HIV 
seronegative subjects p>0.05. (See table1). 
 
Table 1: Comparison of mean ± SD serum levels of Cardiac markers in symptomatic HIV infected subjects on 
ART (A), not on ART (B) and (C) control group (D). 
Group 
 
Myoglobin 
 (ng/mL) 
Troponin 
(ng/mL) 
Ck 
(IU/L) 
CK-MB 
(IU/L) 
LDH  
( IU/L) 
AST  
( IU/L) 
CD4 
(/Ml) 
 
        
A (n=100) 
60.40± 
 32.87 
1.60 ±  
0.25 
122.50 
±17.59 
13.96± 
4.35 
187.22± 
25.25 
31.63± 
9.28 374.78± 121.59 
 
B 
(n=100) 
41.43± 
 13.74 
0.66 ±  
0.16 
102.28 ± 
16.79 
4.88± 
1.64 
157.12 
±25.25 
20.23± 
8.64 437.20 ±129.75 
 
C (n=100) 
30.12± 
 15.03 
0.03 ± 
 0.16 
60.84± 
28.32 
2.51± 
1.51 
155.20 
±23.42 
12.27± 
5.57 940.64± 148.85 
 
F(p)-value 
40.18 
 (.000) 
709.44 
(.000) 
96.98 
(.000) 
245.89 
(.000) 
294.54 
(.000) 
75.65 
(.000) 
216.22  
(.000) 
         A  v B <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
 A v C <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
 B v C <0.05 <0.05 <0.05 <0.05 >0.05 <0.05 <0.05 
 
         
         
          Key:  
  F (p) value = mean ± SD of parameter compared among groups A, B, C and D (using ANOVA). 
A V B p value = mean ± SD of parameter compared between group B and C (using t-test). 
A V C p value = mean ± SD of parameter compared between group B and D (using t-test). 
B V C p value = mean ± SD of parameter compared between group C and D (using t-test). 
4. Discussion 
      In this study, the serum level of Myoglobin, Troponin and serum activities of total CK, CK-MB, LDH and 
AST were significantly higher in HIV positive individuals. Generally, the increases in the levels of both cardiac 
proteins and cardiac enzymes were more marked in symptomatic HIV individuals not on ART. Researchers have 
reported that the increased risk of developing heart disease in HIV individuals may be due to the direct effects of 
the human virus on the heart (Malnick and Goland, 1998), the chronic inflammatory effect of the virus itself on 
the myocardium (Lewis, 2000, Aberg, 2009) and the presence of autoantibodies (Malnick and Goland, 1998).  
    Also, individuals infected with HIV have been linked with heart problem such as pericarditis (Sudano et al, 
2006) and endocarditis (Miro et al, 2003).  
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     In a study, myocardial infarction was observed in HIV subjects (Carr, 2000; Behrens and Schmidt 2005). In 
another study, Friis et al (2003) shows that old age, current or former smoking, previous cardiovascular diseases 
were associated with an increased risk of myocardial infarction.  
  5. Conclusion 
    In this study, we conclude that the serum levels of Myoglobin, Tropinin I and serum activities of total 
Creatine, Creatine -MB, Lactate Dehydrogenase and Aspartate amino transferase were significantly increased in 
adult symptomatic HIV positive subjects. Again, the blood level of CD4+ T cell counts were significantly 
reduced in adult symptomatic HIV positive subjects. This discovery suggests possible impairment of cardiac 
function which may lead to cardiovascular disorder in HIV infection, therefore, the study suggests that the 
prediction of severity and monitoring of disease could be done by evaluating the CD4+ T cell counts, 
Myoglobin, Tropinin I, total Creatine, Creatine -MB, Lactate Dehydrogenase and Aspartate amino transferase in 
HIV infected individuals. Therefore, it is necessary to include these cardiac markers as part of routine tests for 
evaluating the cardiac function of people infected with HIV and malaria. Identification of these biomarkers in 
these individuals will afford more precise and specific tool for early detection, better treatment, better 
management and follow-up.  
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